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Abstract
Hepatitis C virus (HCV) is a major cause of end-stage liver diseases. With 3–4 million new
HCV infections yearly, a vaccine is urgently needed. A better understanding of virus escape
from neutralizing antibodies and their corresponding epitopes are important for this effort.
However, for viral isolates with high antibody resistance, or antibodies with moderate
potency, it remains challenging to induce escape mutations in vitro. Here, as proof-of-con-
cept, we used antibody-sensitive HVR1-deleted (ΔHVR1) viruses to generate escape
mutants for a human monoclonal antibody, AR5A, targeting a rare cross-genotype con-
served epitope. By analyzing the genotype 1a envelope proteins (E1/E2) of recovered Core-
NS2 recombinant H77/JFH1ΔHVR1 and performing reverse genetic studies we found that
resistance to AR5A was caused by substitution L665W, also conferring resistance to the
parental H77/JFH1. The mutation did not induce viral fitness loss, but abrogated AR5A bind-
ing to HCV particles and intracellular E1/E2 complexes. Culturing J6/JFH1ΔHVR1 (genotype
2a), for which fitness was decreased by L665W, with AR5A generated AR5A-resistant
viruses with the substitutions I345V, L665S, and S680T, which we introduced into J6/JFH1
and J6/JFH1ΔHVR1. I345V increased fitness but had no effect on AR5A resistance. L665S
impaired fitness and decreased AR5A sensitivity, while S680T combined with L665S com-
pensated for fitness loss and decreased AR5A sensitivity even further. Interestingly, S680T
alone had no fitness effect but sensitized the virus to AR5A. Of note, H77/JFH1L665S was
non-viable. The resistance mutations did not affect cell-to-cell spread or E1/E2 interactions.
Finally, introducing L665W, identified in genotype 1, into genotypes 2–6 parental and
HVR1-deleted variants (not available for genotype 4a) we observed diverse effects on viral
fitness and a universally pronounced reduction in AR5A sensitivity. Thus, we were able to
take advantage of the neutralization-sensitive HVR1-deleted viruses to rapidly generate
escape viruses aiding our understanding of the divergent escape pathways used by HCV to
evade AR5A.
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Author summary
Worldwide hepatitis C virus (HCV) is one of the leading causes of chronic liver diseases,
including cirrhosis and cancer. Treatment accessibility is limited and development of a
preventive vaccine has proven difficult, partly due to the high mutation rate of the virus.
Recent studies of HCV antibody neutralization resistance have revealed important infor-
mation about escape pathways and barriers to escape for several clinically promising
human monoclonal antibodies. However, due to the varying levels of antibody shielding
between HCV isolates these studies have been mostly limited to a few neutralization-sen-
sitive HCV isolates. Here, we took advantage of the fact that deletion of the hypervariable
region 1 (HVR1) increased antibody sensitivity of HCV isolates by increasing the expo-
sure of important epitopes, thus facilitating studies of antibody escape for neutralization
resistant isolates. We identified escape mutations in the envelope glycoprotein E2, at
amino acid position L665, which conferred antibody resistance in parental HCV viruses
from genotypes 1–6. We found that antibody escape was associated with loss of binding to
HCV particles and intracellular envelope protein complexes. We also identified escape
substitutions at L665 that were isolate-specific. Thus, our data sheds new light on antibody
resistance mechanisms across diverse HCV isolates.
Introduction
About 150 million people are chronically infected with hepatitis C virus (HCV) with an
increased risk of developing end-stage liver diseases, including cirrhosis and hepatocellular
carcinoma [1–3]. Until recently, the treatment against HCV consisted of interferon and ribavi-
rin but its efficacy was limited by side effects and a low rate of sustained virological response
[4]. Progress in understanding HCV virology and the development of in vitro experimental
systems to study antivirals has resulted in new interferon-free therapies [5]. These new treat-
ment regimens consist of combinations of direct-acting antivirals (DAA) with or without riba-
virin with greatly improved response rates. However, the high number of occult infections and
the high cost of DAAs limit access, and the treatment does not provide protection against viral
re-infection [2,6]. Thus, the need for a prophylactic HCV vaccine remains high.
The HCV genome encodes a single polyprotein that is processed into 3 structural proteins
(Core, and envelope proteins E1 and E2), p7 and 6 nonstructural proteins (NS2-NS5B). HCV
is an enveloped single positive-strand RNA virus belonging to the Flaviviridae family, and it is
divided into seven major genotypes based on sequence homology [7,8]. The HCV envelope
glycoprotein complex E1/E2, present on the surface of virus particles, plays a critical role in
viral entry through interactions with cellular receptors such as CD81 [9], scavenger receptor
class B type I (SR-BI) [10], the low-density lipoprotein receptor (LDLr) [11] and several late-
stage host entry factors [12]. The E1/E2 complex is the target of neutralizing antibodies
(NAbs) [13–17]. The presence of NAbs in the early phase of acute HCV infection has been
associated with viral clearance [18,19]. Moreover, passive transfer of monoclonal and poly-
clonal antibodies has conferred protection against HCV infection in experimental animal
models [20–25]. Efforts by several research groups have identified promising NAbs against
HCV [26–33].
Using phage display libraries, human monoclonal antibodies (HMAbs) against conserved
epitopes on E1 and E2 were isolated [27,33]. Epitope-masking allowed for isolation of antibod-
ies against less frequently targeted epitopes [27], and one of these HMAbs, AR5A, which
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recognizes antigenic region 5, showed cross-genotype neutralization activity against cell cul-
tured HCV [27]. Although the high mutation rate of HCV has been shown to enable the virus
to escape neutralization [34–38], the barrier of escape for HMAb AR5A has not been assessed.
The optimal vaccine candidate should induce NAbs against cross-genotype conserved epitopes
with a universally high barrier to resistance.
Previously, antibody-specific resistance mutations have been induced by co-culturing HCV
infected cells with NAbs or by direct neutralization of HCV virus followed by virus amplifica-
tion of the non-neutralized quasispecies [39–43]. However, the variants studied has been lim-
ited to neutralization-sensitive isolates, such as JFH1 [40,41] or the recombinant virus HJ3-5
[43], introducing a potential bias.
Hypervariable regions of the structural glycoprotein E2 can influence neutralization sensi-
tivity [44–46]. We have previously described increased susceptibility of HCV to antibody neu-
tralization when the hypervariable region 1 (HVR1) of E2 is deleted [44,47]. The susceptibility
to antibody neutralization for viruses without HVR1 has been shown to be between 10–1000
fold higher than for the parental virus [44,48]. HVR1 is not essential for infectivity given that
viruses with this region deleted remained infectious in vitro [44;46] and in vivo [44,49,50].
Thus, we anticipated that the HVR1-deleted viruses could be an important tool for the study
of antibody resistance, particularly for mapping conserved residues independent of this highly
variable region frequently used by HCV to escape antibodies.
Here, we used highly sensitive HVR1-deleted variants to study AR5A resistance pathways
for the two isolates H77 (genotype 1a) and J6 (genotype 2a) of medium or high antibody
resistance, respectively; we also attempted escape studies for the original H77 and J6 viruses
retaining HVR1. We induced AR5A-specific escape by culturing the JFH1-based Core-NS2
recombinants H77/JFH1ΔHVR1 and J6/JFH1ΔHVR1 in the presence of AR5A and identified
mutations responsible for escape. Importantly, the mutations were also found to confer resis-
tance in parental viruses. In addition, we were able to induce low-level non-AR5A specific
resistance in H77/JFH1, but not J6/JFH1, by culturing these original viruses with high doses of
AR5A. Finally, we used the JFH1-based Core-NS2 recombinant viruses of genotypes 1–6 to
study resistance against AR5A. The information generated in these studies will be important
to understanding HCV antibody escape, and the novel methodology using HVR1-deleted
viruses could prove useful for designing future studies with other important NAbs against
highly conserved epitopes. Furthermore, the present study provides novel insights into differ-
ent pathways of AR5A virus escape for divergent isolates or even genotypes of this heteroge-
neous virus.
Results
Culturing of highly neutralization-sensitive HVR1-deleted H77/JFH1 with
HMAb AR5A resulted in significantly delayed viral spread and selection
of a resistant virus
On the assumption that the greatly increased sensitivity of HVR1-deleted HCV variants would
make it easier to prevent spread when culturing the viruses in the presence of antibody, we
attempted to generate neutralization escape mutants of HCV by culturing HVR1-deleted H77/
JFH1 (H77/JFH1ΔHVR1) in Huh7.5 cells treated with relatively low doses of AR5A. Huh7.5
cells were infected with this genotype 1a recombinant at a multiplicity of infection (MOI) of
0.001. When the number of infected cells reached 10%, monitored by immuno-staining, cells
were split into 4 wells and cultured either without antibody (untreated) or with 5 μg/ml of
AR5A, which equals ~500 times the IC50 for H77/JFH1ΔHVR1 (treatments I, II, and III, Fig 1A).
Seven days post-treatment the number of infected cells in the untreated well reached >80%,
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however, the number of infected cells in the treated wells decreased until it reached less than
1%. The percent of infected cells in treatment I increased from day 19 and reached >90% at
day 30 post-initiation of antibody treatment. Treatment II and III were followed until day 58
when the cultures were closed due to infection suppresion as evidenced by the absence of anti-
gen-positive cells for more than two weeks.
Culture supernatant of AR5A treated (day 30) and untreated virus (day 7) was used to gen-
erate 1st passage virus stocks by infecting naive Huh7.5 cells. These stock viruses were tested in
a dose-response focus forming units (FFU) reduction assay for AR5A antibody sensitivity (Fig
1B). The AR5A-treated virus was>10,000-fold more resistant against AR5A (Untreated virus
IC50 = 0.0035 μg/ml; Treated virus IC50 > 50 μg/ml), indicating that the virus had escaped the
HMAb. By direct sanger sequencing of the structural genes E1 and E2, we identified substitu-
tions N417D (nucleotide change A1590G) and L665W (T2335G) in E2 (Table 1; all positions
Fig 1. H77/JFH1ΔHVR1 escaped from HMAb AR5A antibody neutralization. (A) Huh7.5 cells were infected
with H77/JFH1ΔHVR1 and treated with 5 μg/ml of AR5A antibody during the indicated period of time. Treatment
I, II, III were treated independently and cultured along with the untreated control. (B) 1st passage of virus
supernatant taken from treatment I and untreated control were subjected to a ten-fold dilution series of AR5A
starting at 50 μg/ml. The virus/antibody mixes along with virus only were added to Huh7.5 cells for 4 hour prior
to wash and addition of fresh medium. Following a total of 48 hour infection the cells were immunostained and
the number of FFUs per well were counted as described in Materials and Methods. Neutralization data are
shown as the mean of four replicates. Neutralization was related to infection of 8 virus replicates in the
absence of antibody. Three-parameter curve-fitting was used to obtain sigmoidal dose-response curves. Error
bars represents the standard errors of the mean.
https://doi.org/10.1371/journal.ppat.1006214.g001
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in the manuscript are given relative to H77 reference strain, GenBank accession number
AF009606) in the AR5A treated virus; the untreated virus did not have any envelope muta-
tions. The amino acid position N417 corresponds to glycosylation site 1 of E2. Thus, the resis-
tant phenotype of the escape virus was likely due to one of these E2 substitutions.
L665W in HCV protein E2 conferred neutralization resistance against
HMAb AR5A
To determine which mutation conferred resistance against AR5A, mutations encoding N417D
and L665W were introduced into H77/JFH1ΔHVR1. Viruses H77/JFH1ΔHVR1, H77/JFH1ΔHVR1/
N417D and H77/JFH1ΔHVR1/L665W reached the peak of infection at day 4 post-transfection.
Additionally, viruses harboring either N417D or L665W had titers similar to or slightly higher
than the control virus H77/JFH1ΔHVR1 (Fig 2A). We generated a 1
st passage stock of all three
Table 1. Coding mutations observed in the HCV envelope proteins. Mutations were found by direct sequence analysis of RT-PCR from recovered
viruses. Red columns denote mutations observed to mediate low-level resistance against both AR3A and AR5A. Blue columns denote mutations shown to be
involved in mediating specific high-level resistance against AR5A. *The mutation was dominant, but a minor a peak of the original nucleotide was observed.
**The following amino acids were observed: HLYNRSIQTVPGK. §Data was taken from Los Alamos on 28th of December 2016. Of note, most isolates pre-
sented in the database are genotype 1, potentially skewing the results. -, No additional amino acids observed across genotypes.
HCV gene E1 E1 E1 E1 E1 E2 E2 E2 E2 E2 E2 E2 E2
Nucleotide number and type
Genome identity J6 J6 H77 S52 S52 J6 H77 S52 H77 S52 H77 J6 J6
Genome position 1124 1373 1386 1403 1455 1563 1589 1702 1940 2096 2334 2346 2390
H77 abs. ref. (AF009606) position 1125 1374 1387 1404 1456 1564 1590 1703 1941 2079 2335 2335 2379
Nucleotide change A!C A!G C!A A!T C!T G!A A!G A!C* A!G T!G T!G T!C T!A
Amino Acid number and type
Polyprotein position 262 345 349 355 372 408 417 454 534 586 665 669 684
H77 abs. ref. (AF009606) position 262 345 349 355 372 408 417 454 534 580 665 665 680
Amino acid change I!L I!V A!D I!F A!V R!K N!D Q!H* T!A F!V L!W L!S S!T
Amino acids observed at least twice in Los Alamos
database§
Within genotype IV ILF ATVG IV ATVGIF RQKS NSD QE TS F L L ST
Across genotypes (unless also within genotypes) LM VA SFL - ML NTAEH - ADGS - ** - - AV
https://doi.org/10.1371/journal.ppat.1006214.t001
Fig 2. Substitution L665W in E2 of HCV increased resistance against antibody AR5A. (A) Huh7.5 cells were transfected with in vitro transcribed
RNA of the indicated recombinants. Supernatants were collected and HCV infectivity titers were determined as indicated in Materials and Methods.
(B) 1st passages of the indicated viruses were subjected to a ten-fold dilution series of AR5A starting at 50 μg/ml. The virus/antibody mixes along with
virus only were added to Huh7.5 cells and after 48 hour infection the cells were immunostained and the number of FFUs per well were counted.
Neutralization data are shown as the mean of four replicates normalized to 8 replicates of virus only. Three-parameter curve-fitting was used to obtain
sigmoidal dose-response curves. Error bars represents the standard errors of the mean. *Virus harbored the substitution T534A (E2).
https://doi.org/10.1371/journal.ppat.1006214.g002
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viruses and their envelope gene sequences were analyzed. While we found no change for H77/
JFH1ΔHVR1 and H77/JFH1HVR1/N417D, we observed the dominant E2 substitution T534A
(A1941G, Table 1) for H77/JFH1ΔHVR1/L665W.
The neutralization sensitivity of these three viruses was compared using a dose-response
FFU reduction assay for AR5A antibody sensitivity (Fig 2B). H77/JFH1ΔHVR1/L665W (IC50 =
49 μg/ml) was highly resistant to antibody neutralization compared to H77/JFH1ΔHVR1/N417D
(IC50 = 0.012 μg/ml) and H77/JFH1ΔHVR1 (IC50 = 0.0035 μg/ml). To rule out that the substitu-
tion T534A, which appeared in the H77/JFH1ΔHVR1/L665W virus, was involved in resistance
against AR5A, we used a highly adapted HVR1-deleted virus, H77/JFH1ΔHVR1/N417D/N532D for
the investigation. We generated stocks of this virus with and without L665W. These virus
stocks did not have any additional changes in the envelope genes and the virus harboring
L665W was fully resistant to antibody neutralization using AR5A (S1 Fig). Thus, we showed
that E2 substitution L665W alone conferred resistance to the HVR1-deleted 1a virus H77/
JFH1 against AR5A.
Substitution L665W in E2 conferred specific neutralization resistance
against HMAb AR5A for parental H77/JFH1 virus retaining HVR1
To test if L665W conferred resistance against AR5A for the parental virus retaining HVR1 we
constructed the recombinant H77/JFH1L665W. Following transfection of Huh7.5 cells with in
vitro transcribed RNA, H77/JFH1 and H77/JFH1L665W both reached titers of about 3.5 Log10
FFU/ml at day 4 post-transfection (Fig 3A). Virus supernatants were used to generate 1st
Fig 3. Parental virus H77/JFH1 with L665W was resistant against AR5A neutralization. (A) Huh7.5 cells were transfected with in vitro
transcribed RNA of the indicated recombinants. Supernatants were collected as indicated and HCV infectivity titers were determined. (B-D) 1st
passages of the indicated viruses were subjected to a five-fold dilution series of HMAb (B) AR5A, (C) AR4A, or (D) AR3A starting at 250 μg/ml. The
virus/antibody mixtures along with virus only were added to Huh7.5 cells and after 48 hour infection the cells were immunostained and the number of
FFUs per well were counted. Neutralization data are shown as the mean of 4 replicates with the standard error of the mean. Neutralization was
related to infection of 8 virus replicates in the absence of antibody. Three-parameter curve-fitting was used to obtain sigmoidal dose-response
curves. Error bars represent standard errors of the mean of 4 determinations.
https://doi.org/10.1371/journal.ppat.1006214.g003
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passage stocks and their envelope sequences were confirmed. Using these virus stocks we com-
pared the susceptibility to AR5A using a dose-response FFU reduction assay (Fig 3B). H77/
JFH1 was completely neutralized at the highest doses of antibody with an IC50 value of 1.9 μg/
ml, whereas H77/JFH1L665W was neutralized less than 50% even at the highest dose used in the
assay (250 μg/ml).
Next, to test if the effects of L665W on H77/JFH1 sensitivity were specific for AR5A, we
tested neutralization sensitivity against HMAbs AR3A and AR4A. These antibodies target con-
formational envelope epitopes that are distinct from the AR5A epitope [27,33]. The antibody
susceptibility against AR4A was similar between the parental virus and H77/JFH1L665W (Fig
3C). However, the susceptibility to AR3A was slightly higher for H77/JFH1L665W (IC50 =
1.5 μg/ml) as compared with the parental virus (IC50 = 10 μg/ml) (Fig 3D), although this effect
was not observed when we performed the analogous neutralization experiments for the
HVR1-deleted virus H77/JFH1ΔHVR1/L665W (S2 Fig). Thus, the mutation L665W conferred spe-
cific resistance against AR5A.
L665W abrogated AR5A binding to the E1/E2 heterodimer, but had no
effect on CD81, SR-BI and LDLr usage during entry
To determine whether the decrease in neutralization sensitivity of H77/JFH1 harboring
L665W was due to impaired binding of the antibody to the particle we performed immunopre-
cipitation of H77/JFH1 and H77/JFH1L665W using HMAbs AR3A, AR4A, and AR5A. We
quantified bead-associated HCV RNA by RT-qPCR and found greatly decreased immunopre-
cipitation of H77/JFH1L665W by AR5A, whereas AR3A and AR4A immunoprecipitation was
similar for the two viruses (Fig 4A). To determine whether AR5A binding was generally
decreased by L665W, even outside the context of a mature virion, we carried out immunos-
taining of cells infected with viruses H77/JFH1 and H77/JFH1L665W using AR5A and AR4A.
We observed a strong AR5A-specific fluorescence signal for H77/JFH1 infected cells, but not
for H77/JFH1L665W infected cells (Fig 4B). In contrast, the antibody AR4A was able to recog-
nize E2 for both viruses (S3 Fig).
Escape mutations in E2 have been shown to change protein structure and reduce binding
to CD81 [51]. To investigate this for virus with L665W, we carried out dose-response entry
blocking using antibodies against the receptors CD81 (Fig 4C), SR-BI (Fig 4D), and LDLr (Fig
4E). H77/JFH1L665W was as susceptible to CD81, SR-BI, and LDLr blocking as the unmodified
virus. Furthermore, H77/JFH1 and H77/JFH1L665W virus entry were similarly reduced by
incubation with soluble CD81 receptor prior to infection (S4 Fig).
HVR1-deleted J6/JFH1 cultured in the presence of HMAb AR5A
developed the envelope substitutions I345V, L665S, and S680T
As AR5A is cross-genotype-reactive we attempted to generate escape mutants for another
HVR1-deleted virus, J6/JFH1ΔHVR1 (genotype 2a). Similar to the approach for H77/JFH1ΔHVR1
we infected Huh7.5 cells with J6/JFH1ΔHVR1 at an MOI of 0.001. After the infection reached
10%, cells were split into 4 wells and cultured without antibody or with antibody at concentra-
tions of 5, 10, or 20 μg/ml of AR5A antibody (Fig 5A). While the control infection reached
>90% infected cells at day 5 post-treatment, cells treated with 5, 10, and 20 μg/ml of AR5A
reached >90% of infection only at day 19, 21, and 23, respectively. Sequences obtained from
AR5A cultures treated with 5 and 10 μg/ml did not show any changes in the envelope proteins.
However, the viral sequence from the supernatant harvested from the culture treated with
20 μg/ml displayed substitutions I345V (A1374G) in E1, and L665S (T2335C) and S680T
(T2379A) in E2 (Table 1). The antibody susceptibility of the 1st passage virus generated from
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the 20 μg/ml treatment was evaluated in a dose-response assay (Fig 5B). Similarly to what we
observed for treated H77/JFH1ΔHVR1, the treated J6/JFH1ΔHVR1 virus (IC50 >50 μg/ml) was
found to be>8000-fold less sensitive to AR5A compared to the parental J6/JFH1ΔHVR1 virus
(IC50 = 0.006 μg/ml).
Envelope substitutions L665S and S680T conferred AR5A resistance to
J6/JFH1 both in the absence and presence of HVR1
Next, we introduced mutations encoding I345V, L665S, and S680T alone or in combination
into J6/JFH1ΔHVR1. Viruses reached >90% of infection 4 days post-transfection. J6/JFH1ΔHVR1
harboring L665S or the combination L665S/I345V had greatly reduced fitness compared to
the parental virus (Fig 6A and Fig 6B). In contrast, viruses containing S680T displayed titers
similar to the parental virus even in combination with L665S and I345V, suggesting S680T was
compensating for the deleterious effects of L665S. We attempted to generate a first passage
Fig 4. L665W decreased AR5A binding to H77/JFH1 particles and to the E1/E2 complex in H77/JFH1 infected cells, but did not alter receptor
dependency. (A) Immunoprecipitation was carried out using anti-E1/E2 antibodies AR5A, AR4A, or the anti-E2 antibody, AR3A, or an irrelevant IgG
as described in Material and Methods. RNA was measured in duplicates by RT-PCR (values given in international units, IU). The results represent the
mean of the total amount of RNA in each sample. The error bar represents standard deviation. *HCV RNA titer below assay cut-off. (B) Huh7.5 cells
were infected with virus H77/JFH1 or H77/JFH1L665W. After 48 hours cells were fixed and incubated with primary antibodies against NS5A (9E10)
and E1/E2 (AR5A). Nuclei were counter-stained using Hoechst. Antibody binding was visualized using specific secondary antibodies coupled to
fluorophores Alexa488 or Alexa594. Images were acquired using a Zeiss Axio Observer Z1. (C-E) Huh7.5 cells were incubated for 1 hour with dilution
series of blocking antibodies against either (C) CD81, (D) SR-BI, or (E) LDLr or control antibody (see Material and Methods for specific antibodies).
The indicated virus supernatants were added to Huh7.5 cells and incubated for 4 hour prior to wash and addition of fresh medium. Following a total of
48 hour infection the cells were immunostained and the number of FFUs per well were counted. Values are means of four replicates and normalized to
8 replicates of virus only. Three-parameter curve-fitting was used to obtain sigmoidal dose-response curves. Errors bars represent the standard errors
of the mean.
https://doi.org/10.1371/journal.ppat.1006214.g004
Multiple escape pathways of HCV to AR5A antibody
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006214 February 23, 2017 8 / 29
stock for every mutant virus however J6/JFH1ΔHVR1/L665S/I345V lost the L665S substitution. J6/
JFH1ΔHVR1/L665S (IC50 = 8.4 μg/ml) was >800-fold more resistant to AR5A than the parental
virus (IC50 = 0.01 μg/ml) (Fig 6C), however it was still>5-fold more susceptible to neutraliza-
tion than J6/JFH1ΔHVR1/L665S/S680T (IC50 = 43 μg/ml) and J6/JFH1ΔHVR1/L665S/I345V/S680T (IC50
>50 μg/ml) (Fig 6D), which were both similarly sensitive as the treated polyclonal escape virus
(Fig 5B). J6/JFH1ΔHVR1/I345V had a neutralization profile similar to the parental virus (Fig 6C).
Remarkably, J6/JFH1ΔHVR1/S680T and J6/JFH1ΔHVR1/I345V/S680T were more susceptible to neu-
tralization with AR5A than J6/JFH1ΔHVR1.
Fig 5. Culturing J6/JFH1ΔHVR1 with AR5A resulted in the selection of a resistant virus. (A) Huh7.5 cells
were infected with virus J6/JFH1ΔHVR1 and treated with 20, 10, or 5 μg/ml of AR5A antibody during the indicated
period of time. (B) 1st passage of virus supernatant from the 20 μg/ml treatment and the untreated control were
subjected to a ten-fold dilution series of AR5A starting at 50 μg/ml. The virus/antibody mixes along with virus only
were added to Huh7.5 cells and after 48 hour infection the cells were immunostained and the number of FFUs per
well were counted. Neutralization data are shown as the mean of 4 replicates. Neutralization was related to
infection in the absence of antibody. Three-parameter curve-fitting was used to obtain sigmoidal dose-response
curves. Error bars represent the standard error of the mean.
https://doi.org/10.1371/journal.ppat.1006214.g005
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Substitutions I345V, L665S, and S680T affected viability of parental J6/JFH1 in a similar
way as described above for J6/JFH1ΔHVR1 (Fig 7A and Fig 7B). 1
st passage virus stocks were
prepared for all the viruses, and again J6/JFH1L665S/I345V lost the L665S mutation while J6/
JFH1L665S had a partial reversion of L665S. All other mutant viruses were generated success-
fully with no additional envelope mutations. The virus J6/JFH1L665S did not appear resistant to
AR5A, however, this could be due to the partial loss of the mutation. Viruses J6/JFH1L665S/
S680T (IC50 > 250μg/ml) and J6/JFH1L665S/I345V/S680T (IC50 > 250 μg/ml) were>7-fold more
resistant to antibody neutralization for AR5A than the parental virus (IC50 = 36 μg/ml) (Fig
7D). Similar to what we observed for the HVR1-deleted virus, the antibody susceptibility
increased when viruses had the mutation S680T without L665S (Fig 7C and Fig 7D). Our
results confirmed that the mutation L665S together with S680T conferred resistance to J6/
JFH1 against AR5A.
Changes in cell-to-cell spread not involved in AR5A resistance
To test whether L665W (for H77/JFH1ΔHVR1) or L665S and S680T (for J6/JFH1ΔHVR1) were
influencing cell-to-cell spread we transfected Huh7.5 cells with HVR1-deleted HCV recombi-
nants with and without these substitutions and mixed the transfected cells with naive cells
either in the absence or in the presence of high levels of NAb, AR3A (to prevent cell-free
spread). L665S decreased both cell-free and cell-to-cell spread (in line with our observations
on the negative effect of this mutation on virus fitness, Fig 6A) whereas none of the other
mutations had any effect on cell-to-cell spread (S5 Fig), indicating that changes in cell-to-cell
spread were not the reason for the resistance of viruses harboring substitutions at residues 665
and 680.
Fig 6. The substitutions L665S and S680T in E2 are both required to confer complete AR5A resistance to J6/JFH1ΔHVR1 without affecting
virus fitness. Huh7.5 cells were transfected with in-vitro transcribed RNA of the recombinant viruses with (A) single or (B) combined substitutions
I345V, L665S, and S680T. Supernatants were collected at the indicated time-points and HCV infectivity titers were determined. 1st passages of the
viruses with (C) single or (D) combined substitutions I345V, L665S and S680T were subjected to a ten-fold dilution series of AR5A starting at 50 μg/
ml. The virus/antibody mixes along with virus only were added to Huh7.5 cells and after 48 hour infection the cells were immunostained and the
number of FFUs per well were counted as described in Materials and Methods. Neutralization values are the mean of four replicates and normalized
to eight replicates of virus only. Three-parameter curve-fitting was used to obtain sigmoidal dose-response curves. Error bars represent the
standard error of the mean.
https://doi.org/10.1371/journal.ppat.1006214.g006
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HCV was highly sensitive to most changes at the conserved E2 position
L665, none of which altered the level of E1/E2 interaction
Substitutions L665W and L665S decreased susceptibility against AR5A neutralization for viruses
H77/JFH1 and J6/JFH1, respectively. To analyze the effects on viability and AR5A neutralization
sensitivity of other amino acid substitutions we generated H77/JFH1 recombinants with serine
(S), alanine (A), valine (V), tyrosine (Y), and threonine (T) at position 665. Viruses with substitu-
tions L665Y and L665V were less infectious and the remaining substitutions rendered the virus
non-viable resulting in the absence of infectious particles at the four tested time points post-trans-
fection (Fig 8A). We attempted to generate 1st passage virus stocks of H77/JFH1 harboring either
L665Y or L665V, however infection with these viruses did not result in efficient viral spread and
infected cells were not detected 3 weeks post-infection. Our data suggests that a very limited num-
ber of isolate-specific substitutions are allowed at this conserved E2 position. To address whether
the decreased viability of the L665 mutants was due to perturbation of the E1/E2 interaction we
performed immunoprecipitation (using the E2-conformational antibody, AR3A) of native E1/E2
complexes from 293T cells transiently expressing E1E2 in cis. Western blots of the E2-enriched
fractions showed comparable levels of both E2 and the co-immunoprecipitated E1 protein (Fig
8B), strongly indicating that E1/E2 interaction was conserved for all L665 mutants.
Culturing H77/JFH1 and J6/JFH1, retaining HVR1, in the presence of
high doses of AR5A resulted in limited or no escape
To evaluate whether substitutions at position 665 or 680 could be induced by culturing H77/
JFH1 or J6/JFH1 in the presence of AR5A similar treatments as the ones described above were
performed. Here, H77/JFH1 and J6/JFH1 were used to infect naive Huh7.5 cells at an MOI of
Fig 7. The substitution L665S combined with S680T conferred AR5A resistance to the parental recombinant virus J6/JFH1. Huh7.5 cells
were transfected with in-vitro transcribed RNA of the indicated recombinant viruses with (A) single or (B) combined mutations. Supernatants were
collected at the indicated time-points and HCV infectivity titers were calculated. 1st passages of the viruses with (C) single or (D) combined
mutations were subjected to a five-fold dilution series of AR5A starting at 250 μg/ml. The virus/antibody mixes along with virus only were added to
Huh7.5 cells and after 48 hour infection the cells were immunostained and the number of FFUs per well were counted. Neutralization data are
shown as the mean of four replicates with the standard error of the mean. Neutralization was related to eight replicates of virus only. Three-
parameter curve-fitting was used to obtain sigmoidal dose-response curves. Error bars represent standard errors of the mean. *Virus partially lost
the substitution L665S.
https://doi.org/10.1371/journal.ppat.1006214.g007
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0.001. Once the virus spread to 1% of the cells both were cultured either without antibody or
at the AR5A dose for which escape mutations were identified for the HVR1-deleted counter-
parts (5 μg/ml and 20 μg/ml, respectively), as well as a high dose of 200 μg/ml. Not surprisingly,
only the high dose resulted in delayed viral spread (Fig 9A and 9B). Sequence analysis of the
envelope protein encoding sequences from the treated cultures identified the unique coding
substitution A349D (C1387A) for H77/JFH1 and R408K (G1564A) for J6/JFH1 in the samples
treated at 200 μg/ml (Table 1).
Fig 8. Position L665 in HCV E2 is highly sensitive to amino-acid substitutions. (A) The leucine at
position 665 in H77/JFH1 was substituted for the indicated amino acids, and Huh7.5 cells were transfected
with in vitro transcribed RNA of recombinants harboring these substitutions. Supernatants were collected at
the indicated time-points and HCV infectivity titers were determined as described in Materials and Methods.
(B) 293T cells were transiently transfected with vectors expressing L665 mutants of H77 E1E2 in cis. E1/E2
protein complexes were gently released using 1% nDDM detergent with protease inhibitors and benzonase.
The samples were subjected to AR3A (conformational E2-specific antibody) immunoprecipitation and
SDS-PAGE and western blot transfer was performed on the enriched fractions. E2 was detected using
antibody H52 and E1 was detected using antibody A4.
https://doi.org/10.1371/journal.ppat.1006214.g008
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These viruses were passaged to generate virus stocks with sequence-confirmed envelope
proteins harboring these substitutions and without additional coding changes in the envelope
proteins. In dose-response neutralization experiments against AR5A it was clear that the muta-
tion A349D conferred low level resistance to H77/JFH1 (~8-fold, Fig 9C), whereas the muta-
tion R408K had no effect on neutralization sensitivity of J6/JFH1 (Fig 9D). Interestingly, the
mutation A349D also conferred low level resistance against AR3A (~12-fold, Fig 9E), but not
AR4A (Fig 9F).
To test the effect of the mutations on virus viability we constructed the recombinants H77/
JFH1A349D and J6/JFH1R408K. Following transfection of Huh7.5 cells with in vitro transcribed
Fig 9. Culturing H77/JFH1 and J6/JFH1 with AR5A resulted in low or negligible escape. (A-B) Huh7.5 cells were infected with (A) H77/JFH1
and treated with 5 μg/ml (treatment I) or 200 μg/ml (treatment II) of AR5A or with (B) J6/JFH1 and treated with 20 μg/ml (treatment I) or 200 μg/ml
(treatment II) of AR5A. Treatments were performed independently and cultured along with the untreated control. (C-D) 1st passage of virus
supernatant taken from treatment II for both viruses and untreated control were subjected to a three-fold dilution series of AR5A, starting at 250 μg/ml.
(E-F) The AR5A resistant H77/JFH1 virus from treatment II was subjected to neutralization with (E) AR3A and (F) AR4A as described above. The
virus/antibody mixes along with virus only were added to Huh7.5 cells for 4 hour prior to wash and addition of fresh medium. Following a total of 48 hour
infection the cells were immunostained and the number of FFUs per well were counted as described in Materials and Methods. Neutralization data are
shown as the mean of four replicates. Neutralization was related to infection of 8 virus replicates in the absence of antibody. Three-parameter curve-
fitting was used to obtain sigmoidal dose-response curves. Error bars represents the standard errors of the mean.
https://doi.org/10.1371/journal.ppat.1006214.g009
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RNA and infectivity titration of transfection supernatants it was evident that the mutation
A349D increased the infectivity titer of H77/JFH1, whereas the mutation R408K had no effect
on the infectivity of J6/JFH1 (S6A and S6B Fig). Thus, our data suggests that it is very difficult
to induce specific escape mutations for resistant or even moderately resistant HCV recombi-
nants as the virus is able to spread even at high antibody doses without acquiring specific resis-
tance mutations.
L665W conferred varied fitness cost across HCV genotypes 1–6, but
universal AR5A resistance
Alignment of the E2 protein of the genotype 1a (H77), 2a (J6), 3a (S52), 4a (ED43), 5a (SA13),
and 6a (HK6a) [52–54] revealed that the position L665 was conserved across these genotype
1–6 isolates, and indeed also universally conserved in the Los Alamos sequence database
[55] (Table 1) and the European HCV database [56]. Since AR5A has demonstrated cross-
genotype neutralizing potential [27,57], it was interesting to test whether changes at position
L665 could confer AR5A-resistance in other HCV genotypes. Using the JFH1-based Core-NS2
HCV recombinants harboring envelope protein sequence from genotype 2a (J6), 3a (S52), 4a
(ED43), 5a (SA13), and 6a (HK6a) [54;58–61] we introduced the mutations encoding L665W.
The parental and the HVR1-deleted viruses with or without L665W were tested for all the
genotypes except genotype 4 HVR1-deleted virus which was non-viable [44]. The effect of
L665W on viral fitness varied greatly (Fig 10). While the parental and HVR1-deleted SA13/
JFH1 viruses were virtually unaffected (Fig 10D), L665W seemed to attenuate both parental
and HVR1-deleted J6/JFH1 (Fig 10A) and HK6a/JFH1 (Fig 10E), as well as the parental ED43/
JFH1 (Fig 10C). On the other hand, L665W only affected the viability of the parental S52/JFH1
but not the HVR1-deleted counterpart (Fig 10B).
We used supernatants from each transfection culture to infect Huh7.5 cells and generated
1st passage stocks of each virus. The virus J6/JFH1ΔHVR1/L665W developed the substitution
I262L (A1125C, Table 1), the virus S52/JFH1L665W developed I355F (A1404T, Table 1) and the
virus S52/JFH1ΔHVR1/L665W developed A372V (C1456T, Table 1), Q454H/q (A1703C/a,
Table 1) and F580V (T2079G, Table 1). The remaining virus stocks did not acquire coding
mutations in the envelope genes. Using these virus stocks we tested if the substitution L665W
affected AR5A susceptibility across genotypes and found that it broadly decreased sensitivity
to AR5A neutralization (Fig 11). The change in antibody susceptibility caused by L665W was
higher for the HVR1-deleted viruses than for the parental viruses, most likely due to the gener-
ally increased neutralization sensitivity of the HVR1-deleted variants.
Finally, we compared neutralization sensitivity against the HMAb AR3A (S7 Fig) and
AR4A (S8 Fig) for the different genotype viruses harboring L665W. With a few exceptions the
neutralization susceptibility was unaffected by the introduction of L665W. J6/JFH1ΔHVR1/
L665W was 20-fold less susceptible to neutralization with AR3A; this was not the case for the
parental virus J6/JFH1L665W (S7A Fig). Virus ED43/JFH1L665W was more susceptible to neu-
tralization with both AR3A (S7C Fig) and AR4A (S8C Fig), in contrast both parental and
HVR1-deleted SA13/JFH1 viruses were more resistant to antibody neutralization with AR3A
(S7D Fig) and AR4A (S8D Fig). The other viruses had unaltered neutralization susceptibility
against AR3A and AR4A. Thus, we concluded that overall L665W in E2 specifically reduced
sensitivity against AR5A across HCV genotypes.
Discussion
We identified different pathways of neutralization escape from the HMAb AR5A using the
highly antibody susceptible HVR1-deleted viruses H77/JFH1ΔHVR1 and J6/JFH1ΔHVR1 and the
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original viruses H77/JFH1 and J6/JFH1. The mutation A349D, found by culturing H77/JFH1
with a high dose of AR5A, conferred broader low-level neutralization resistance for H77/JFH1.
Mutations encoding amino acid changes at the highly conserved position L665, found by cul-
turing neutralization sensitive HVR1-deleted H77/JFH1 and J6/JFH1 with at least 10-fold
lower doses of AR5A, conferred specific high-level resistance against AR5A for both viruses,
with and without HVR1, whereas mutation S680T was required to compensate for fitness loss
as well as further increasing AR5A-specific resistance for J6/JFH1 and J6/JFH1ΔHVR1. In addi-
tion, we also observed several cases of adaptive mutations in the envelope proteins that likely
also contributed to the ability of the virus to overcome AR5A neutralization. Finally, while we
observed divergent, isolate-dependent, pathways to AR5A resistance we showed that substitu-
tions at L665 could confer resistance across HCV genotypes 1–6, highlighting the potential
importance of this position in AR5A resistance.
Fig 10. Differential fitness impact of the substitution L665W on prototype isolates of HCV genotypes 1–6. Mutations encoding L665W was
introduced into cell-cultures adapted HCV Core-NS2 recombinants with or without HVR1 of genotypes (A) 2a (J6/JFH1), (B) 3a (S52/JFH1), (C)
4a (ED43/JFH1), (D) 5a (SA13/JFH1) and (E) 6a (HK6a/JFH1). Huh7.5 cells were transfected with in vitro transcribed RNA of the indicated
recombinants. Supernatants were collected at the indicated time-point and HCV infectivity titers were determined as indicated in Materials and
Methods.
https://doi.org/10.1371/journal.ppat.1006214.g010
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The development of an effective vaccine will be a cost-effective way to control HCV-associ-
ated liver disease worldwide [38;62;63]. In vitro studies of antibody resistance against HMAbs
is important for HCV vaccine development to understand potential challenges with resistant
viruses. Previous studies demonstrated an overlap between mutations found in resistant vari-
ants isolated in vitro and escape mutations identified from in vivo infection [39;40;42;43;64].
The relevance of in vitro escape studies has been shown for HMAb CBH-2, for which resistant
variants had developed mutations at position D431 [40], also identified in a naturally occur-
ring CBH-2 resistant variant [42]. Moreover, mutations at position N415 and N417 have been
identified during in vitro escape studies against the antibody AP33 [39;43] and mutations at
these same positions were also observed in resistant viruses found in liver transplant patients
treated with HCV1, a HMAb recognizing the same E2 antigenic site [64]. Thus, in vitro escape
studies can provide useful information on resistance pathways and barriers to resistance for
virus NAb escape. Our previous findings that combinations of antibodies can have synergistic
effects in neutralizing HCV [57], would be well complemented by detailed analyses concerning
the barrier to resistance for these interesting epitopes.
The inherent broad neutralization antibody-resistance of some HCV isolates hinders the
study of escape mutations for these viruses, partly due to the excessive amounts of antibody
needed to suppress viral spread [65]. One way to minimize the use of HMAbs is to treat sensi-
tive HCV recombinants such as the original JFH1, which is also not highly efficient in cell cul-
ture making it difficult for the virus to outgrow the antibody. Escape variants of JFH1 were
isolated by culturing in the presence of around 10- or 50-times the IC50 concentrations of
HMAbs CBH-2 or HC-11, respectively [40]. A distinct approach that reduced the amount of
antibody relied on several iterations of a single neutralization step of the highly sensitive
recombinant virus HJ3-5 with AP33 prior to inoculation of naive cells with the non-neutral-
ized viruses [43]. The escaped variants were isolated by 3 rounds of antibody neutralization
with>100 times the IC50 (100 μg/ml) of the antibody followed by amplification of the non-
Fig 11. Substitution L665W increased AR5A resistance of HCV genotypes 1–6. 1st passage virus stocks of the indicated viruses were
subjected to a dilution series of AR5A and the IC50 was determined for virus with (A) and without HVR1 (B). Numbers represent the number of
times that the IC50 of a HCV virus with L665W is higher than its parental virus. J6/JFH1L665W harbored the substitution I262L, S52/JFH1L665W
harbored the substitution I355F and S52/JFH1ΔHVR1/L665W harbored the substitutions A372V, Q454H/q and F580V. *IC50 could not be
determined as less than 50% neutralization was observed at the highest tested AR5A concentration.
https://doi.org/10.1371/journal.ppat.1006214.g011
Multiple escape pathways of HCV to AR5A antibody
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006214 February 23, 2017 16 / 29
neutralized virus. However, the resistant viruses showed a considerable reduction of viral
fitness indicating that the escaped virus needed additional mutations to compensate for the
fitness loss. Another approach has been to passage the virus first in low doses of antibody fol-
lowed by increasingly higher doses in subsequent passages, in the hope that escape will develop
gradually under the low selective pressure. This approach has been shown to generate multiple
JFH1 escape variants against HMAb HC33.1 [41]. While these are innovative solutions, they
demand large amounts of antibody to generate escape variants for resistant HCV recombi-
nants as shown in the case of selecting Jc1 (genotype 2a recombinant) escape mutants to AP33
[39]. Jc1 was serially passaged in the presence of AP33 at increasing concentrations up to ~40
times of the IC90 concentration (i.e. 200 μg/ml) [39].
There is currently no good way to induce escape mutations in naturally resistant HCV
isolates (such as J6/JFH1) leading to a potential bias of the studied viruses and concomitantly
the escape barriers. Here, we induced AR5A-specific escape in H77/JFH1ΔHVR1 and J6/
JFH1ΔHVR1 at antibody doses (5 μg/ml and 20 μg/ml, respectively) that would be easily over-
come by the parental viruses (Fig 9A and 9B). In fact, we were unable to induce escape muta-
tions in J6/JFH1 even at 200 μg/ml (the highest dose we have observed others use to generate
NAb escape [39]) and only induced low level (~8-fold) resistance at this high dose for H77/
JFH1, which was not specific to AR5A. This highlights another advantage of using HVR1-de-
leted viruses to study specific NAb escape as it eliminates the acquisition of mutations in the
envelope proteins that could contribute to a general increase in neutralization resistance thus
impeding direct identification of antibody-specific escape mutations [66]. Here, we studied
the moderately neutralization sensitive H77/JFH1 and the generally resistant J6/JFH1 (IC50
values against AR5A for H77/JFH1 and J6/JFH1 of 1.9 μg/ml and 36 μg/ml, respectively). The
HVR1-deleted viruses had drastically reduced, and similar, IC50 values (IC50 was 0.0035 μg/ml
for H77/JFH1ΔHVR1 and 0.0065 μg/ml for J6/JFH1ΔHVR1). Thus the deletion of HVR1 allowed
us to induce escape at 5 μg/ml and 20 μg/ml of HMAb AR5A for H77/JFH1ΔHVR1 and J6/
JFH1ΔHVR1, respectively. Interestingly, while H77/JFH1ΔHVR1 and J6/JFH1ΔHVR1 were simi-
larly sensitive to neutralization with AR5A the latter was able to outgrow the antibody at 5 and
10 μg/ml. Although viral spread was significantly delayed, we did not observe escape variants
following treatment of J6/JFH1ΔHVR1 with AR5A concentrations lower than 20 μg/ml, thus
indicating that the highly infectious J6/JFH1ΔHVR1 was able to simply outgrow the antibody.
Thus, it seems that viability of the virus used in escape studies is an important factor to con-
sider when selecting the appropriate concentration of antibody. However, it should be noted
that the viability of H77/JFH1 is similar to J6/JFH1ΔHVR1 indicating that decreased viability of
HVR1-deleted viruses does not, by itself, explain why it is relatively easy to inhibit viral spread
at low doses of antibody. In addition, using low multiplicities of the IC50 values of antibody
others have isolated mutations that did not specifically affect virus susceptibility [39;41].
Thus, a high multiplicity of the IC50 values could be essential to the rapid isolation of resistant
variants.
We propose that the use of the highly neutralization susceptible HVR1-deleted viruses
allows for the isolation of antibody-specific resistant variants for otherwise neutralization-
resistant HCV recombinants and eases the generation of escaped viruses for multiple isolates
of different HCV genotypes. However, since the deletion of HVR1 has been shown to affect
receptor interactions and the lipid composition of the viral particles [44;67], more studies
using other NAbs are needed to evaluate if escape results obtained using the HVR1-deleted
variants will have general relevance.
We identified escape mutations that arose in viruses cultured in the presence of AR5A.
These mutations can be grouped according to their effects on virus susceptibility to AR5A
and on virus viability. The only resistance mutation we identified through culturing viruses
Multiple escape pathways of HCV to AR5A antibody
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006214 February 23, 2017 17 / 29
retaining HVR1 with AR5A was the substitution A349D, which was found by culturing H77/
JFH1 at a high dose of AR5A. The mutation also conferred low level resistance against AR3A
and could be similar in this respect to envelope mutations that broadly modulate NAb resis-
tance such as those described by others [68–70]. However, it should be noted that aspartic acid
(D) was not observed at this position in the Los Alamos database (Table 1), indicating that it is
not a natural polymorphism. We identified two different mutations at position L665 (L665W
for H77/JFH1 and L665S for J6/JFH1). Previously, we mapped the AR5A binding site to posi-
tion R635 with an alanine substitution resulting in a reduction of relative binding of AR5A by
50–75% [27]. In the same study the alanine substitution at position L665 decreased the relative
binding level of AR5A by 60%. However, since alanine is smaller than leucine and both amino
acids are non-polar, the alanine scanning could be underestimating the importance of position
L665 in AR5A binding. In contrast, the bigger amino acid group of tryptophan and the polar-
ity of serine could induce the conformational change necessary to impair antibody binding.
We showed that L665W abrogated AR5A binding to HCV particles and to intracellular E1/
E2 protein, while also greatly increasing resistance to AR5A neutralization for genotype 1–6
viruses. It should be noted that while we are not able to provide evidence for whether the dif-
ferent pathways to resistance against AR5A are isolate or genotype dependent the high enve-
lope protein heterogeneity between the genotype isolates we have tested for AR5A resistance
does represent the high diversity of HCV. Recently, we showed that polymorphisms at posi-
tions 636 and 708 could be involved in the higher resistance against HMAb AR5A of the HCV
strain S52 [48], however the effect in resistance was lower than the one induced by the muta-
tion L665W in the same genotype. Thus, our data strongly indicates that L665 is a part of the
AR5A epitope. L665 was universally conserved in E2 sequences deposited in the Los Alamos
HCV database [55] and the European HCV database [56] (Table 1), and the decrease in virus
fitness for isolates from genotypes 2, 3, 4, and 6 with L665W suggests that L665 is important
for virus infectivity. It has previously been shown that highly conserved epitopes tend to have a
higher barrier to resistance, probably due to their importance in critical interactions [28;40].
However, we found that while L665 was highly conserved the barrier to resistance was isolate-
dependent. The observed differences in the escape mutations for viruses with and without
HVR1 suggests that it might be of interest in future studies to attempt to induce escape for
viruses with and without HVR1 and with non-viral neutralization epitopes in their envelope
proteins, such as the flag-epitope with neutralizing potential at the N-terminus of E2 [71], to
investigate how escape mutations for such epitopes would cluster.
L665 is localized within the stem region that connects the E2 ectodomain to the C-terminal
transmembrane region [72]. We previously proposed that the stem region could play a role in
virus entry [73], however, E2 protein with the stem and transmembrane regions deleted could
still interact with host entry factors [74]. Here, we did not observe any changes in receptor
dependency for viruses harboring the mutation L665W. Furthermore, in a few cases L665W
altered the sensitivity to other conformational antibodies suggesting it might have some effects
on the structure of the E1/E2 complex. However, the substitutions at this position did not
seem to affect E1/E2 interactions or cell-to-cell spread. It is conceivable that the mutations
affect some other critical entry process, such as viral fusion. It will be of interest in future stud-
ies to further elucidate the role of this conserved site.
During the treatment with AR5A we observed the mutation N417D for H77/JFH1ΔHVR1
and I345V for J6/JFH1ΔHVR1. These mutations did not significantly alter AR5A susceptibility
but increased viral fitness. Higher fitness of a treated virus seems to be an important predictor
of whether the virus can outgrow a NAb as we previously proposed upon treatment in culture
of the highly infectious HCV recombinant SA13/JFH1 [58]. The mutation N417D abolished
the first N-linked glycan of the E2 protein and has been implicated both in increasing virus
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infectivity and in protecting the virus from NAbs [75]. Since we did not observe any change in
antibody susceptibility, it is possible that the glycosylation at position N417 does not protect
AR5 or even that the glycan shield is less effective in shielding HVR1-deleted viruses. The sub-
stitution N417T shifts the glycan at N417 to N415 and has been implicated in resistance against
AP33, which targets the epitope at 412–423 [39]. In a separate study with another 412–423 spe-
cific antibody, HC33.1, the mutation N417T appeared at low concentrations of antibody, but
was probably increasing fitness of the virus rather than conferring specific escape [41]. The
mutation I345V is novel, but the near-adjacent substitution, I347L, has been identified as a
compensatory mutation adapting the HVR1-deleted Jc1 virus to cell culture [46]. Thus, the
two adaptive envelope mutations N417D and I345V are probably decreasing the effectiveness
of AR5A in culture through increased viral fitness.
The substitution S680T was of interest as it compensated for the fitness loss of L665S in J6/
JFH1 and also increased AR5A-specific resistance. However, S680T had the opposite effect on
neutralization sensitivity in the absence of L665S, hinting at a complex relationship between
positions 665 and 680 while also suggesting that S680 is not part of the AR5A epitope. Several
studies have described mutations that can indirectly alter HCV antibody susceptibility without
themselves being a part of the antibody epitope [41;51;68;69;76]. Moreover, the phenotype of
some of these mutations has been shown to depend on the envelope protein context [41;68].
However, S680T appears to be unique, as it modulates AR5A sensitivity in a position-
665-dependent manner and simultaneously compensates for the lower viability of viruses har-
boring the L665S escape mutation. Since H77/JFH1 has threonine at position 680 (as does
most genotype 1, 3, 4 and 5 isolates of HCV, whereas genotype 2 and 6 typically have serine at
this position) and the virus H77/JFH1L665S was not viable, our results indicate that the com-
pensatory effect of S680T for mutation L665S was specific for J6/JFH1, indicating that the two
pathways to resistance (L665W for H77/JFH1 and L665S/S680T for J6/JFH1) are likely, at least
partly, isolate-dependent. It is important that we observed isolate-dependent pathways requir-
ing either one or two mutations to confer complete resistance of a viable virus as the former
would be considered to have a low barrier to resistance whereas the other is relatively high.
Using HVR1-deleted viruses enable researchers to perform escape studies of multiple isolates
from different genotypes, providing relevant information even for otherwise resistant isolates,
such as J6/JFH1.
In conclusion, using neutralization-sensitive HVR1-deleted viruses we were able to gener-
ate escape viruses in vitro against the HMAb AR5A. We showed that the selective pressure can
result in different escape mutations depending on the envelope protein sequence. We identi-
fied novel escape mutations at positions either involved directly in binding, such as L665S and
L665W or indirectly, such as S680T. Our data emphasizes the complexity of viral resistance
against conformational antibodies, in this case HMAb AR5A, and highlights the importance of
studying resistance using multiple isolates, preferably both of high and low inherent neutrali-
zation sensitivity. These important findings are only attainable through escape studies and are
highly relevant in the context of viral infectivity and fitness. The knowledge gained concerning




Human monoclonal antibodies AR3A, AR4A, and AR5A against HCV structural proteins
were produced as described previously [27;33]. Antibodies against HCV receptors were anti-
CD81 (BD Pharmingen Cat. JS81), anti-SR-BI C16-17 [67;77] and polyclonal anti-LDLr (R&D
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Systems Cat. AF2148). Control antibodies for receptor blocking assays were the isotype anti-
body 553447 for CD81, the antibody D for SR-BI [77], and a goat IgG (R&D Systems Cat. AB-
108C) for LDLr. Soluble CD81 protein was a kind gift from Steven Foung [73]. Adapted
recombinants with the core-NS2 sequence from genotypes 1a (H77), 2a (J6), 3a (S52), 4a
(ED43), 5a (SA13) and 6a (HK6a) and UTR´s as well NS3-NS5B region from genotype 2a
(JFH1) with or without HVR1 were described previously [44;54;58–61]. H77 E1E2 expression
plasmids, previously validated for functionality in HCVpp assays [67], were used for E1/E2
interaction studies. Plasmids with point mutations were generated by conventional cloning
techniques (Fusion PCR and Quikchange). The HCV sequence of the final plasmid DNA prep-
arations were confirmed by direct sequencing (Macrogen). Antibody against NS5A, 9E10 [61],
was provided by Charles Rice.
Cell culture of Huh7.5 cells
Huh7.5 cells [78], provided by Charles Rice, were cultured in Dulbecco’s modified eagle
medium DMEM (Gibco/Invitrogen Corporation, Carlsbad, CA) supplemented with 10% of
heat-inactivated fetal bovine serum (FBS), penicillin 100 U/mL and streptomycin 100 μg/mL
(Gibco/Invitrogen Corporation) at 5% of CO2 at 37˚C. Cells were split every 48 to 72 hours.
Virus stocks were generated by low MOI infection of naive Huh7.5 cells. Supernatants were
collected at the peak of infection, then filtered and stored at -80˚C. HCV envelope ORF
sequencing from culture supernatants was done by long RT-nested PCR procedures, as
described [44;54;58–60].
Transfection of Huh7.5 cells
Huh7.5 cells were plated at 4x105 per well in 6-well plates 24 hours prior to transfection at
which point they were ~70% confluent. Plasmids were linearized by XbaI treatment (New
England BioLabs). RNA was generated by T7-mediated in-vitro transcription and was trans-
fected into Huh7.5 cells using lipofectamine 2000 (Invitrogen). 6 hours post transfection,
Huh7.5 cells were trypsinized and reseeded into four wells of 24-well plates at a cell density of
8x104 (for the 4 time-points of the assay) along with plating in 6-well chamber slides for assess-
ing percent infected cells at the four time-points, using the primary mouse anti-HCV NS5A
9E10 antibody and the secondary antibody Alexa488 goat anti-mouse IgG (H+L) (Invitrogen)
as described [59] and Hoechst 33342 (Molecular Probes) counterstain for nuclei. Viral spread
was monitored every 24 hours along with harvesting of virus supernatant up to 96 hours post
transfection. Supernatants collected during experiments were sterile filtered and stored at
−80˚C. The virus titers were determined as described previously [79, 80].
HCV escape assay
Huh7.5 cells (~70% confluent) were infected with HCV virus H77/JFH1 or J6/JFH1 with or
without HVR1 at an MOI of 0.001 and incubated in 5% of CO2 at 37˚C. Virus infection was
monitored by immuno-staining every 2–3 days as described above. After the virus infection
spread to 1–10%, the indicated concentrations of antibody AR5A were added in each well.
Supernatants were collected and filtered when cell infection reached 80–90% of the cells.
HCV neutralization
6x103 Huh7.5 cell per well was plated in poly-D-lysine 96-well plates and incubated for
24 hours. Next day, a volume of virus stock corresponding to a read-out of 50–300 focus form-
ing units per well (FFUs/well) were incubated in quadruplicates with a dilution series of
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monoclonal antibody and relevant control antibody. Virus-antibody mixes along with eight
replicates of virus only were incubated for 1 hour at 37˚C and were added to Huh7.5 cells
(~70% confluent) and incubated for 4 hours at 37˚C and 5% CO2. Subsequently, the cells were
washed and fresh medium was added prior to incubation for a total infection time of 48 hours.
Cells were fixed and stained with 9E10 antibody as described previously [59]. The data was
normalized to 8 replicates of virus only and analyzed using three or four parameters curve fit-
ting in GraphPad Prism [67]. In all cases, the neutralization data were confirmed in two inde-
pendent experiments.
HCV receptor blocking
6x103 Huh7.5 cells per well was plated in poly-D-lysine 96–well plates and incubated for 24
hours. The next day the Huh7.5 cells were incubated in four replicates with a 1 to 5 dilution
series of monoclonal antibody against CD81 or SR-BI receptors or the polyclonal antibody
against LDLr and four replicates of the respective control antibodies at the highest concentra-
tions used in the assay. A volume of virus stock corresponding to a read-out of 50–300 FFUs/
well of HCV were added to the cell-antibody mix and incubated for 4 hours at 37˚C (cells were
~70% confluent at time of infection). Cells were washed and fresh medium was added prior to
incubation for a total infection time of 48h. Cells were fixed and stained with 9E10 antibody as
described [59]. The data was normalized to 8 replicates of virus only and analyzed using four
parameters curve fitting in GraphPad Prism. Blocking data were confirmed in two indepen-
dent experiments.
Cell-to-cell spread
Huh7.5 cells were plated at 400.000 cells/well in 6-well plates and the following day the cells
were transfected with HCV RNA transcripts (cells were ~70% confluent) as previously
described [59]. The following day cells were trypsinized and mixed with naive trypsinized
Huh7.5 cells prior to plating at 12,000 Huh7.5 cells per well in poly-D-lysine 96–well plates
(NUNC). 6 wells per plate for each virus condition were seeded along with 12 wells per plate
with only naive Huh7.5 cells to estimate background staining on each plate. A ratio of trans-
fected/naive cells of 1:150 was used for cells plated in standard medium and a ratio of 1:30 was
used for cells plated in standard medium in the presence of 10 μg/ml of the cross-genotype
reactive HCV neutralizing antibody, AR3A [33]. This dose represented at least 500-fold the
IC50 value for the tested HVR1-deleted viruses [48]. 6 replicates of cell mixes from each virus
construct were plated in the absence or presence of AR3A for fixation at the two time-points;
24 hours and 48 hours post-plating. At 24 hours and 48 hours a plate was fixed in methanol
and all plates were subsequently stained for infection using the NS5A-specific antibody, 9E10.
Number of single infected cells, number of focus forming units (clusters of single cells) and
size of FFUs were counted and calculated using adapted BioSpot software (Cellular Technol-
ogy Lmtd.). Data was analyzed using GraphPad Prism.
E1/E2 interaction assay
293T cells (American Type Culture Collection, ID: CRL-1573) were plated at 400.000 cells/
well in a 6-well plate and the following day the cells were transfected using Lipofectamine 2000
(Invitrogen) with 5 μg of E1E2 expression plasmids. The following day the cells were replated
back into the 6-well plate except for the plating of two slides. The next day the slides were fixed
with 4% paraformaldehyde at room temperature for 15 minutes and the cells were permeabi-
lized with 0.1% Tween20. Subsequently the slides were stained for E2 or E1/E2 using AR3A or
AR4A, respectively, followed by incubation with anti-human Alexa488 coupled secondary
Multiple escape pathways of HCV to AR5A antibody
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006214 February 23, 2017 21 / 29
antibody and Hoechst 33342 (Molecular Probes) counterstain for nuclei. Transfection efficien-
cies were comparable. Cells in 6-wells were lysed using a 1% nDDM detergent in NativePAGE
sample buffer (Novex life technologies/Thermo Scientific) supplemented with 1x Halt protease
inhibitor cocktail (Thermo Scientific) by pipetting the solution up and down several times.
The lysates were cleared by centrifugation at 4˚C at 20.000xrcf for 30 minutes. The samples
were transferred to fresh tubes, MgCl2 was added in a final concentration of 2mM and samples
were treated with Benzonase endonuclease (Sigma) for 30 min prior to immunoprecipitation
with the conformationally-reactive E2 antibody, AR3A, using Protein G coupled Dynabeads
(Thermo Scientific) as per the manufacturer´s instructions. The E1/E2 protein complexes
were eluted directly into LDS buffer by heating the beads for 10 minutes at 70˚C. The E1/E2
protein complexes were loaded onto SDS-PAGE gels and run for 1 hour at 200 V under reduc-
ing conditions. This was followed by transfer onto a PVDF membrane at 35 V for 1 hour. E2
protein was visualized using mouse H52 antibody [81] and E1 protein was visualized on sepa-
rate membranes using mouse A4 antibody [82] incubated overnight at 4˚C on a shaker fol-
lowed by incubation with anti-mouse coupled with horse radish peroxidase for 1 hour at room
temperature on a shaker. The Supersignal West Femto Chemi-luminescence (Thermo Scien-
tific) kit was used. The size of proteins was estimated by using the Precision Plus Protein Wes-
ternC standard (Bio-Rad) size marker as per the manufacturer´s instructions.
Soluble CD81 neutralization
We plated 6x103 Huh 7.5 cell per well in poly-D-lysine 96-well plates and incubated for 24
hours. Next day, a volume of virus stock corresponding to a read-out of 50–300 FFUs/well of
HCV was incubated in four replicates with a dilution series of soluble CD81 receptor protein.
Virus-CD81 mixes along with eight replicates of virus only were incubated for 1 hour at 37˚C
and were added to Huh7.5 cells (~70% confluent) and incubated for 4 hours at 37˚C and 5%
CO2. Subsequently, the cells were washed and incubated for a total infection time of 48h with
fresh medium. Cells were fixed and stained with the 9E10 antibody as described [59]. The data
was normalized to 8 replicates of virus only and analyzed using four parameters curve fitting
in GraphPad Prism. Experiments data were confirmed in two independent experiments.
Immuno-staining with antibodies AR4A and AR5A
Huh7.5 cells were infected with viruses H77/JFH1 or H77/JFH1L665W with a multiplicity of
infection (MOI) equal to 0.01 and incubated for 24 hours. We plated 2.5x104 infected Huh7.5
cells per well in an 8 wells slide and incubated them for an additional 24 hours. Cells were
fixed with para-formaldehyde at room temperature for 15 minutes and the cells were permea-
bilized with 0.1% Tween20. Antibody anti-NS5A in combination with either AR4A or AR5A
was used as primary antibodies. We used a combination of Alexa594 goat anti-mouse IgG (H
+L) (Invitrogen) and Alexa488 goat anti-human (Invitrogen) as secondary antibodies with a
Hoechst 33342 (Molecular Probes) counterstain for nuclei.
HCV RNA immunoprecipitation
Immunoprecipitation was carried out using the immunoprecipitation kit Dynabeads Protein
G (Thermo Scientific) as previously described [67]. We used 5 μg of antibodies AR3A, AR4A
or AR5A along with a relevant isotype antibody control b6. Magnetic bead-associated HCV
RNA was eluted with lysis buffer from the QIAmp MinElute Vacuum kit (Qiagen) and the
HCV RNA was extracted using the kit protocol together with a dilution series of a standard
sample with a known HCV RNA concentration and a blank solution. HCV RNA was eluted in
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30μl of elution buffer and 8μl of each sample was used for reverse transcription-quantitative
PCR (RT-qPCR) using a Light Cycler as described before [59;67].
Supporting information
S1 Fig. Substitution L665W conferred resistance in the cultured-adapted H77/JFH1ΔHVR1
virus. 1st passages of the indicated viruses were subjected to a ten-fold dilution series of AR5A
starting at 50 μg/ml. The virus/antibody mixes along with virus only were added to Huh7.5
cells and after 48 hour infection the cells were immunostained and the number of FFUs per
well were counted as described in Materials and Methods. Neutralization data are shown as
the mean of four replicates with standard error of the mean and normalized to eight replicates
of virus only. Three-parameter curve-fitting was used to obtain sigmoidal dose-response
curves. Error bars represent standard errors of the mean.
(TIF)
S2 Fig. L665W did not generate resistance against the HMAb AR3A or AR4A in HVR1-de-
leted H77/JFH1 virus. 1st passages of the indicated viruses were subjected to a ten-fold dilu-
tion series of antibodies (A) AR3A or (B) AR4A starting at 50 μg/ml. The virus/antibody mixes
along with virus only were added to Huh7.5 cells and after 48 hour post infection the cells
were immunostained and the number of FFUs per well were counted. Neutralization data are
shown as the mean of four replicates with standard error of the mean and normalized to eight
replicates of virus only. Three-parameter curve-fitting was used to obtain sigmoidal dose-
response curves. Error bars represent standard errors of the mean.
(TIF)
S3 Fig. The HMAb AR4A binding to cells infected with virus H77/JFH1 was not affected
by the substitution L665W. Huh7.5 cells were infected with virus H77/JFH1 or H77/
JFH1L665W were immune stained with primary antibodies against NS5A (9E10) and E1/E2
(AR4A), and specific secondary antibodies coupled to fluorophores Alexa488 or Alexa594.
Nuclei were stained using Hoechst.
(TIF)
S4 Fig. L665W did not affect virus inhibition by soluble CD81 neutralization. Viruses H77/
JFH1 and H77/JFH1L665W were subjected to a five-fold dilution series of soluble CD81 recep-
tor starting at 50 μg/ml. The virus/antibody mixtures along with virus only were added to
Huh7.5 cells and after 48 hour post infection the cells were immunostained and the number of
FFUs per well were counted as described in Materials and Methods. Neutralization data are
shown as the mean of four replicates with the standard error of the mean. Neutralization was
related to eight replicates of virus only. Three-parameter curve-fitting was used to obtain sig-
moidal dose-response curves. Error bars represent standard errors of the mean.
(TIF)
S5 Fig. Cell-to-cell spread of HCV was not specifically affected by the AR5A-specific escape
substitutions L665W, L665S and S680T. Huh7.5 cells were transfected with the indicated
viral constructs including JFH1ΔE1E2 as a negative control. These were mixed with naive cells
and plated at 12,000 cells/well in 96 well plates to ensure nearly 100% cell confluence. Trans-
fected cells were diluted 1:150 with naive Huh7.5 cells for wells left untreated with neutralizing
AR3A antibody and 1:30 for wells treated with AR3A. Number of FFUs, size of FFUs and
number of single infected cells were counted for the 6 replicates of each virus condition using
automated BioSpot software (Cellular Technology Lmtd.) following HCV-specific staining
after 24 hour and 48 hour. Error bars indicate SD. (A) Average number of FFUs per well for
Multiple escape pathways of HCV to AR5A antibody
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006214 February 23, 2017 23 / 29
wells not treated with AR3A antibody. (B) Average number of FFUs per well for wells treated
with AR3A antibody. (C) Average size of FFUs in wells treated with AR3A. (D) Number of sin-
gle infected cells per FFU in wells treated with AR3A.
(TIF)
S6 Fig. The substitution A349D increased infectivity of H77/JFH1 whereas R408K had no
effect on infectivity of J6/JFH1. Huh7.5 cells were transfected with in vitro transcribed RNA
of the indicated (A) H77/JFH1 or (B) J6/JFH1 recombinants. Supernatants were collected and
HCV infectivity titers were determined as indicated in Materials and Methods.
(TIF)
S7 Fig. AR3A neutralization of HCV prototype isolates of genotypes 1–6 with and without
L665W. 1st passage virus stocks of the indicated viruses were subjected to dilution series of
AR3A. The virus/antibody mixes along with virus only were added to Huh7.5 cells and after 48
hour infection the cells were immunostained and the number of FFUs per well were counted.
Values are means of four replicates and normalized to 8 replicates of virus only. Three-param-
eter or four-parameter curve-fitting was used to obtain sigmoidal dose-response curves. Errors
bars represent the standard errors of the mean. Virus harbored the substitution I262L. †Virus
harbored the substitution I355F. ‡Virus harboring substitutions A372V, Q454H and F580V.
(TIF)
S8 Fig. AR4A neutralization of HCV prototype isolates of genotypes 1–6 with and without
L665W. 1st passages of the indicated viruses were subjected to dilution series of AR4A. The
virus/antibody mixes along with virus only were added to Huh7.5 cells and after 48 hour post
infection the cells were immunostained and the number of FFUs per well were counted. Val-
ues are means of four replicates and normalized to 8 replicates of virus only. Three-parameter
or four-parameter curve-fitting was used to obtain sigmoidal dose-response curves. Errors
bars represent the standard errors of the mean. Virus harbored the substitution I262L. †Virus
harbored the substitution I355F. ‡Virus harboring substitutions A372V, Q454H and F580V.
(TIF)
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